Test Price
2,800 AEDโ Home Collection Available
TRAPPC9 Gene Intellectual Disability (Autosomal Dominant Type 13) Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
This advanced genetic test provides definitive molecular diagnosis of TRAPPC9-related autosomal dominant intellectual disability type 13. With 99.9% diagnostic sensitivity via ISO 9001:2015 accredited processing (Cert: INT/EGQ/2509DA/3139), the analysis employs targeted next-generation sequencing to detect pathogenic single-nucleotide variants and small indels. Patients receive comprehensive support including VIP mobile phlebotomy and temperature-controlled cold-chain home collection, followed by telephonic post-test clinical guidance from our DHA-licensed genetics specialist.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection & VIP Mobile Phlebotomy.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by DHA-licensed specialists.
- Insurance: Direct Billing Verification via WhatsApp: +971 54 548 8731.
Test Overview & Methodology
The TRAPPC9 Genetic Test utilizes targeted next-generation sequencing (NGS) to interrogate the entire coding region and splice junctions of the TRAPPC9 gene. This approach identifies heterozygous pathogenic variants responsible for autosomal dominant intellectual disability type 13, enabling accurate molecular diagnosis and informed genetic counseling.
| Feature | Our TRAPPC9 NGS Test | Chromosomal Microarray (CMA) Alternative |
|---|---|---|
| Methodology | Targeted Next-Generation Sequencing (NGS) | Microarray-based Copy Number Analysis |
| Diagnostic Precision | Detects single-nucleotide variants and small indels with >99.9% sensitivity | Detects large deletions/duplications, misses point mutations |
| Turnaround Time | 3โ4 Weeks | 4โ6 Weeks |
| Clinical Recommendation | First-line for suspected TRAPPC9-related intellectual disability | Screening for chromosomal anomalies |
Physician Insight & Safety Protocols
โAs a Consultant Medical Genetics, I underscore that this targeted NGS test provides definitive molecular evidence for TRAPPC9-related intellectual disability. The result must always be correlated with comprehensive clinical, developmental, and family history assessment. Early identification through this assay empowers families with accurate recurrence risks and enables tailored interventional strategies. Genetic counseling before and after testing is essential for informed decision-making.โ โ Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory
Do not alter or discontinue any prescribed medications prior to or following this test without explicit direction from your treating neurologist or geneticist. The test itself does not require medication adjustments.
Exclusion Criteria & Red Flags
- This test is not intended for acute neurological crises; immediately attend to sudden loss of consciousness, new-onset seizures, or stroke-like symptoms via emergency services.
- Individuals unable to provide informed consent require a legally authorized representative, compliant with Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Results do not replace full clinical evaluation; discuss findings with a clinical geneticist or neurologist.
- For minors, consent must be obtained from a legal guardian in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Rapidly progressive cognitive decline, acute behavioral deterioration, or suspected neurodegenerative crisis necessitating immediate in-person assessment: do not rely solely on this genetic test.
Patient FAQ & Clinical Guidance
1. What is the accuracy of this TRAPPC9 genetic test?
Our ISO-accredited NGS platform delivers over 99.9% diagnostic sensitivity for TRAPPC9 pathogenic variants, reliably detecting point mutations and small indels in the target gene. This ensures a high-confidence molecular diagnosis for autosomal dominant intellectual disability type 13.
2. How is the sample collected for this test in the UAE?
A certified phlebotomist will perform a standard blood draw either at our facility or via our VIP mobile phlebotomy service. Acceptable specimens include whole blood (3โ5 mL in EDTA tube), extracted DNA, or dried blood spot on an FTA card. All samples are transported under strict temperature-controlled cold-chain conditions to ensure integrity.
3. Do I need genetic counseling before taking this test?
Yes, pre-test genetic counseling is mandatory. Our clinical geneticist will collect a detailed family pedigree, discuss the implications of possible results (including variants of uncertain significance), and ensure you provide fully informed consent. Post-test counseling is also included to explain findings and guide next steps.
4. How long does it take to get results?
The turnaround time is 3โ4 weeks from sample receipt in the laboratory. This duration accounts for sequencing, bioinformatic analysis, variant interpretation, and clinical report generation by our genetics team.
5. Is home collection available for this test?
Yes, home collection is available daily from 8 AM to 11 PM through our VIP Mobile Phlebotomy service. A trained phlebotomist will come to your residence, collect the sample under sterile conditions, and transport it via our cold-chain courier. Additional charges apply; contact +971 54 548 8731 for scheduling and pricing.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance Framework
This genetic test is performed in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All clinical data and genetic information are handled with strict confidentiality, encrypted storage, and access controls. The laboratory adheres to DHA guidelines and maintains ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139). Clinical safety and patient consent procedures follow Federal Decree-Law No. 4 of 2016 on Medical Liability.
For any data privacy concerns, contact our Data Protection Officer via WhatsApp: +971 54 548 8731.
Clinical & Logistical Metadata
| Test Name | TRAPPC9 Gene Intellectual Disability (Autosomal Dominant Type 13) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3โ4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA), Extracted DNA, or Dried Blood Spot (FTA Card) |
| Methodology Used | Targeted Next-Generation Sequencing (NGS) โ Illumina Platform |
| ICD-10-CM Code | F79 (Unspecified intellectual disabilities) |
| LOINC Code | 101023-7 (TRAPPC9 gene mutation analysis in Blood or Tissue by Sequencing) |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab Branding: DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians